Editorial

From the desk of the editor

Welcome to the May 2013 edition of i2P - Information to pharmacists.
Economic turbulence seems to now be arriving in Australia with forecasts of high inflation rates, which also means high interest rates following on.
This type of economic forecast also means that banks will be more fractious with their borrowers. They are already offside with pharmacy due to the high level of bankruptcies over the past two years.
There is a pent up demand for a general wage increase for pharmacists impacting at a point in this month where pharmacy gross profit generally, is in decline.

read more
open full screen

Columns

Recent Comments

Click here to read...

Past Editions

Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 4 Number 1
Volume 4 Number 2
Volume 4 Number 3
Volume 4 Number 4
Volume 4 Number 5
Volume 4 Number 6
Volume 4 Number 7
Volume 4 Number 8
Volume 4 Number 9
Volume 4 Number 10
Volume 4 Number 11
Volume 5 Number 1
Volume 5 Number 2
Volume 5 Number 3
Volume 5 Number 4

i2P Archives

Health Politics

EPublications

Click here for a list of epublications

New survival factor for immune cells identified

• Printer-friendly version
• Send to friend
• PDF version
• Share

	Staff Researcher articles by this author...
Editing and Researching news and stories about Australian and International Pharmacy Issues

Ms Eleonora Ottina and Dr Marco Herold have identified a survival factor for immune cells
An international team of researchers has discovered that many of the body’s infection-fighting immune cells require a cell survival protein, called A1, to develop and function. Their finding could lead to a better understanding of conditions including leukaemia, allergy and autoimmunity.
The team discovered that without A1, immune cells called lymphocytes and granulocytes could not develop, or could not respond appropriately to infectious stimuli.

open this article full screen

A1 is part of the Bcl-2 protein family, which controls the survival of cells. The research team developed a method of depleting A1 from immune cells, allowing them to study the development and function of immune cells lacking A1. The findings were published online last month in the journal Blood.

The research was jointly led by Dr Marco Herold, from the Walter and Eliza Hall Institute’s Molecular Genetics of Cancer division, and Dr Andreas Villunger of Innsbruck Medical University, Austria, a former postdoctoral researcher at the institute. Dr Herold, who began the research while at the University of Wuerzburg, Germany, said the discovery had surprised many scientists working in the area. “For more than a decade, we have known that cell survival proteins such as Bcl-2 are important for immune cell development and function,” he said. “A1 proved more difficult to work with than other, closely related, proteins so many researchers ignored it. Our work has shown that A1 has many important roles in the immune system.”

Ms Eleonora Ottina, a student visiting the institute from the Molecular Cell Biology and Oncology post-graduate program at Innsbruck Medical University, said the discovery had opened the door to several new fields of research into human disease. “It is well known that conditions including leukaemia, allergy, and autoimmune conditions, such as lupus, can be caused by the survival of defective or unwanted immune cells, which should normally die,” she said.

“Our research has shown that A1 is important for immune cell development and survival, and has given us the tools to deplete cells of A1 protein. We are now working to determine whether the presence of A1 in cells is necessary for the development of leukaemia, autoimmunity or allergy. If it is, depleting or functionally blocking A1 could be a new treatment for these diseases.”

The research was funded by the Austrian Science Fund (FWF), the Tiroler Krebshilfe and the German Research Council.

Clinical Newsfeed

Click here to read more...

Research Reports

Practice Development

Preventive Medicine

i2P Alliance Partners